4.07
-0.06 (-1.45%)
| Previous Close | 4.13 |
| Open | 4.20 |
| Volume | 629,154 |
| Avg. Volume (3M) | 850,007 |
| Market Cap | 457,872,544 |
| Price / Sales | 5.56 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Profit Margin | -197.64% |
| Operating Margin (TTM) | -123.58% |
| Diluted EPS (TTM) | -1.42 |
| Quarterly Revenue Growth (YOY) | 27.60% |
| Current Ratio (MRQ) | 4.46 |
| Operating Cash Flow (TTM) | -136.07 M |
| Levered Free Cash Flow (TTM) | -110.34 M |
| Return on Assets (TTM) | -27.02% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ADC Therapeutics SA | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.13 |
|
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 21.58% |
| % Held by Institutions | 66.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Redmile Group, Llc | 30 Jun 2025 | 15,666,731 |
| Prosight Management, Lp | 30 Jun 2025 | 10,467,771 |
| Orbimed Advisors Llc | 30 Jun 2025 | 5,907,351 |
| Heights Capital Management, Inc | 30 Jun 2025 | 2,832,861 |
| Nantahala Capital Management, Llc | 30 Jun 2025 | 2,266,289 |
| Platinum Investment Management Ltd | 30 Jun 2025 | 1,387,265 |
| Woodline Partners Lp | 30 Jun 2025 | 842,900 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (Guggenheim, 145.70%) | Buy |
| Median | 8.50 (108.85%) | |
| Low | 7.00 (HC Wainwright & Co., 71.99%) | Buy |
| Average | 8.50 (108.85%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 3.61 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 16 Oct 2025 | 7.00 (71.99%) | Buy | 4.13 |
| Guggenheim | 13 Aug 2025 | 10.00 (145.70%) | Buy | 3.09 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Oct 2025 | Announcement | ADC Therapeutics Announces $60 Million Private Placement |
| 01 Oct 2025 | Announcement | ADC Therapeutics Makes Grants to New Employees Under Inducement Plan |
| 02 Sep 2025 | Announcement | ADC Therapeutics Makes Grants to New Employees Under Inducement Plan |
| 27 Aug 2025 | Announcement | ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025 |
| 12 Aug 2025 | Announcement | ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update |
| 05 Aug 2025 | Announcement | ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025 |
| 01 Aug 2025 | Announcement | ADC Therapeutics Makes Grants to New Employees Under Inducement Plan |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |